PharMerica Corp. (NYSE:PMC)’s share price was down 2.7% during trading on Monday . The company traded as low as $26.00 and last traded at $26.00, with a volume of 128,862 shares trading hands. The stock had previously closed at $26.72.

A number of equities analysts have commented on PMC shares. TheStreet downgraded PharMerica Corp. from a “buy” rating to a “hold” rating in a research note on Monday, May 9th. Zacks Investment Research upgraded PharMerica Corp. from a “hold” rating to a “strong-buy” rating and set a $30.00 target price for the company in a research note on Thursday, May 12th. Barrington Research restated an “outperform” rating and issued a $34.00 target price (up from $30.00) on shares of PharMerica Corp. in a research note on Tuesday, May 10th. Finally, Bank of America Corp. started coverage on PharMerica Corp. in a research note on Tuesday, June 7th. They issued a “buy” rating and a $32.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. PharMerica Corp. presently has a consensus rating of “Buy” and a consensus target price of $31.57.

The firm has a market capitalization of $807.38 million and a price-to-earnings ratio of 27.36. The stock has a 50-day moving average of $25.59 and a 200 day moving average of $25.17.

PharMerica Corp. (NYSE:PMC) last announced its quarterly earnings data on Friday, May 6th. The company reported $0.45 EPS for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.02. The company had revenue of $524.50 million for the quarter, compared to analyst estimates of $509.45 million. During the same period in the prior year, the company posted $0.48 EPS. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. Analysts anticipate that PharMerica Corp. will post $2.02 EPS for the current year.

Several hedge funds and institutional investors recently made changes to their positions in PMC. Russell Frank Co raised its position in shares of PharMerica Corp. by 8.3% in the fourth quarter. Russell Frank Co now owns 29,018 shares of the company’s stock worth $1,016,000 after buying an additional 2,213 shares in the last quarter. Trexquant Investment LP raised its position in shares of PharMerica Corp. by 148.9% in the fourth quarter. Trexquant Investment LP now owns 30,140 shares of the company’s stock worth $1,055,000 after buying an additional 18,031 shares in the last quarter. California State Teachers Retirement System raised its position in shares of PharMerica Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 56,285 shares of the company’s stock worth $1,970,000 after buying an additional 885 shares in the last quarter. Redwood Investments LLC raised its position in shares of PharMerica Corp. by 6.3% in the fourth quarter. Redwood Investments LLC now owns 58,400 shares of the company’s stock worth $2,044,000 after buying an additional 3,444 shares in the last quarter. Finally, California Public Employees Retirement System raised its position in shares of PharMerica Corp. by 3.8% in the fourth quarter. California Public Employees Retirement System now owns 111,808 shares of the company’s stock worth $3,913,000 after buying an additional 4,100 shares in the last quarter.

PharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals, provides specialty infusion services to patients outside a hospital setting and offers the national oncology pharmacy in the United States.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.